Incyte, MorphoSys' CAR-T rival tafasitamab approved in EU

Incyte and MorphoSys' antibody therapy tafasitamab has been approved in Europe, promising to provide a more convenient alternative to expensive and cumbersome CAR-T therapies for patients w